pharmaphorum

MARCH 3, 2022

Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs.

Insulin 52

Insulin Production Generic Drugs FDA Approval 52

pharmaphorum

MARCH 23, 2022

The US Senate will vote in the coming weeks on whether to introduce a $35 cap on the monthly cost of insulin to patients that was endorsed by President Joe Biden in his 2022 State of the Union address. Assuming the bill is later passed by the Senate and signed into law by President Biden, the insulin cap would take effect beginning in 2023.

Insulin 73

Insulin Generic Drugs Production FDA Approval 73

FDA Law Blog

NOVEMBER 16, 2021

That section of the bill – along with the other accompanying sections and parts of the bill – would amend Title XI of the Social Security Act to create a new part – Part E – requiring the HHS Secretary to establish a “Fair Price Negotiation Program” intended to lower prices for certain high-priced single-source drugs and biological products.

Generic Drugs 52

Generic Drugs Manufacturing Drugs Licensing 52

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 6, 2021

Pandemic Delayed Some FDA Plant Inspections, Product Approvals ( Bloomberg ) ( Pink Sheet ). Taking double Covid-19 hits, Merck writes off $170M for scrapped drug, highlights $600M in missed sales ( Endpoints ). Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year ( STAT ).

Sales 52

Sales Vaccination Vaccine Gene Therapy 52

Pharmaceutical Technology

DECEMBER 4, 2022

For example, the first-to-market status was beneficial when it came to insulin biosimilars. Citing studies comparing such products, there are no important differences between biosimilars and their branded counterpart, says Arnold Vulto, PharmD, professor of hospital pharmacy at Erasmus University, Rotterdam.

Marketing 262

Marketing Pharmacy Production Branding 262

Pharmacy Checkers

MARCH 11, 2020

The standard required to permit lawful wholesale importation, part (b)-(h) from Canada is that it “ pose no additional risk to the public’s health and safety and would be expected to result in a significant reduction in the cost of covered products to the American consumer.”. vs. $30 in the Canada.

Pharmacy 41

Pharmacy Drugs FDA Approval Licensing 41